HONG KONG SAR – Media OutReach Newswire – December 22, 2023 – Recently, KPMG China led a delegation of executives, senior managers of biotechnology companies China comes to explore investment and business opportunities in many rapidly growing markets in Southeast Asia and Asia-Pacific. Southeast Asia and the Asia-Pacific region have emerged as important destinations for the global expansion of biotechnology, driven by strong cooperation between China and the region through through the Belt and Road Initiative. This survey trip continues the opportunity exploration activity through the successful organization of KPMG China's Middle East Forum in May 2023.
At the 6-day on-site forum from December 4 to 9, 20 executives and senior managers from Chinese biotechnology companies visited famous institutions in China. Singapore and Indonesia, including the Singapore Economic Development Board (EDB), Agency for Science, Technology and Research (A*STAR), Garea Technology, Rxilient Health Pte. Ltd. (Rxilient), DBS Bank, China International Capital Corporation (CICC), China-Singapore Suzhou Industrial Park Development, Indonesian Ministry of Health, PT Etana Biotechnologies Indonesia (Etana) , UBC Medical Technology Company, Tigermed, CFLD…
These visits provided invaluable insights into local market dynamics, regulatory landscape, research and development (R&D) infrastructure and clinical research facilities. The forum facilitated discussions on globalization roadmaps and effective implementation plans.
Mr. Frank Mei, Head of KPMG Asia Pacific and China Enterprise Risk Management Services and KPMG China Life Sciences Consulting Manager, shared insights on the development of the global pharmaceutical market, the development and prospects of China's biotech innovation as well as the rapid growth of domestic R&D activities in recent times. He also provided an overview of policy support, capital, enhanced R&D capacity, enhanced affordability and potential business models for Chinese companies operating in Asia – Pacific.
Mr. Frank Mei was invited to give a keynote speech at APACMed's China-ASEAN MTF session, analyzing the emerging trends of MedTech in the ASEAN market, the potential of Chinese enterprises, and building strategies Strong business development models. He highlighted KPMG China's strategic initiative to assist Chinese biotech companies in entering emerging markets globally, providing comprehensive support throughout the entire project lifecycle. judgment.
During his visit to the Indonesian Ministry of Health, Mr. Fran Hou, Life Sciences Division Manager of KPMG China, also highlighted the importance of ecosystem collaboration to enhance patient experience.
The Chinese biotech delegation visited KPMG Offices in Singapore and Indonesia, meeting with KPMG's global life sciences partners responsible for the European Union (EU), UK and US at Singapore. The conversations and exchanges focused on the growth and development of Chinese biotech companies in the global market.
Going forward, KPMG China will continue to support Chinese biotech companies in navigating emerging markets globally, contributing to driving advances in innovation and healthcare. Strong.
Hashtag: #KPMGChina
The publishing source is solely responsible for the content of this announcement.
Hashtag: #KPMGChina
The issuer is solely responsible for the content of this announcement.